Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.75 SEK | -3.20% | -9.73% | +3.05% |
Sales 2024 * | 65.08M 5.95M | Sales 2025 * | 471M 43.05M | Capitalization | 1.68B 154M |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.6M | Net income 2025 * | 105M 9.6M | EV / Sales 2024 * | 27.4 x |
Net Debt 2024 * | 103M 9.38M | Net cash position 2025 * | 61.97M 5.66M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
8.41
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on Egetis Therapeutics AB
1 day | -3.20% | ||
1 week | -9.73% | ||
Current month | -13.92% | ||
1 month | -12.88% | ||
3 months | -3.52% | ||
6 months | +16.04% | ||
Current year | +3.05% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
CHM | Chairman | 73 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.75 | -3.20% | 568,552 |
24-04-25 | 5.94 | +0.17% | 152,280 |
24-04-24 | 5.93 | -5.57% | 271,959 |
24-04-23 | 6.28 | +0.32% | 137,986 |
24-04-22 | 6.26 | -1.73% | 180,763 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.05% | 153M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- EGTX Stock